Q32 Bio Statistics

Total Valuation

Q32 Bio has a market cap or net worth of $351.81 million. The enterprise value is $234.44 million.

Market Cap	351.81M
Enterprise Value	234.44M

Important Dates

The next estimated earnings date is Monday, August 5, 2024, before market open.

Earnings Date	Aug 5, 2024
Ex-Dividend Date	n/a

Share Statistics

Q32 Bio has 11.94 million shares outstanding. The number of shares has increased by 577.31% in one year.

Shares Outstanding	11.94M
Shares Change (YoY)	+577.31%
Shares Change (QoQ)	-27.53%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	n/a

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	993.83
Forward PS	n/a
PB Ratio	7.21
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	662.27
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 4.19, with a Debt / Equity ratio of 0.38.

Current Ratio	4.19
Quick Ratio	n/a
Debt / Equity	0.38
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -452.60% and return on invested capital (ROIC) is -131.78%.

Return on Equity (ROE)	-452.60%
Return on Assets (ROA)	-65.30%
Return on Capital (ROIC)	-131.78%
Revenue Per Employee	$9,568
Profits Per Employee	-$2.25M
Employee Count	37
Asset Turnover	0.00
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +63.67% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+63.67%
50-Day Moving Average	23.32
200-Day Moving Average	17.85
Relative Strength Index (RSI)	73.36
Average Volume (20 Days)	124,804

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Q32 Bio had revenue of $354,000 and -$83.09 million in losses. Loss per share was -$32.43.

Revenue	354,000
Gross Profit	354,000
Operating Income	-88.76M
Pretax Income	-83.09M
Net Income	-83.09M
EBITDA	-80.77M
EBIT	-83.09M
Loss Per Share	-$32.43

Full Income Statement

Balance Sheet

The company has $135.96 million in cash and $18.59 million in debt, giving a net cash position of $117.37 million or $9.83 per share.

Cash & Cash Equivalents	135.96M
Total Debt	18.59M
Net Cash	117.37M
Net Cash Per Share	$9.83
Equity (Book Value)	48.77M
Book Value Per Share	4.08
Working Capital	105.09M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$84.73 million and capital expenditures $554,000, giving a free cash flow of -$84.17 million.

Operating Cash Flow	-84.73M
Capital Expenditures	554,000
Free Cash Flow	-84.17M
FCF Per Share	-$84.57

Full Cash Flow Statement

Margins

Gross margin is 100.00%, with operating and profit margins of -25,073.73% and -23,471.19%.

Gross Margin	100.00%
Operating Margin	-25,073.73%
Pretax Margin	-23,471.19%
Profit Margin	-23,471.19%
EBITDA Margin	-22,815.82%
EBIT Margin	-23,471.19%
FCF Margin	-23,777.68%

Dividends & Yields

Q32 Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-577.31%
Shareholder Yield	-577.31%
Earnings Yield	-23.62%
FCF Yield	-23.93%

Analyst Forecast

The average price target for Q32 Bio is $62.25, which is 111.30% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$62.25
Price Target Difference	111.30%
Analyst Consensus	Strong Buy
Analyst Count	4
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Q32 Bio has an Altman Z-Score of -0.64 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.64
Piotroski F-Score	1